DiscGenics closed a Series B financing round.
Here are five points:
1. The company, which develops regenerative therapies for degenerative spine diseases, earned $14 million in funding.
2. DiscGenics now has $21.7 million in total funding.
3. DiscGenics board of directors' long-term investors and Mitsubishi UFJ Capital Co. led the round.
4. The company is developing IDCT, an injectable cell therapy for degenerative disc disease.
5. The funding will support the company's clinical development of IDCT in the U.S and Japan as well as boost its cell therapy manufacturing process for Phase III clinical and commercial production.